Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.950 HKD | +0.68% | -3.28% | -20.91% |
08-30 | Citi Upgrades Luye Pharma to Buy From Sell; Price Target is HK$4 | MT |
08-28 | Luye Pharma Group Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 | CI |
Executive Committee: Luye Pharma Group Ltd.
Manager | Positions heldSince | ||
---|---|---|---|
Dian Bo Liu 59 year |
| ||
Rong Bing Yang 58 year |
| ||
Mei Yi Lee 56 year |
|
Composition of the Board of Directors: Luye Pharma Group Ltd.
Director | CommitteesSince | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dian Bo Liu 59 year |
| ||||||||||||
Rui Lin Song 61 year |
| ||||||||||||
Yuk Lam Lo 76 year |
| ||||||||||||
Man Kit Leung 71 year |
| ||||||||||||
Hua Qiao Zhang 60 year |
| ||||||||||||
Sze Chung Choy 65 year |
| ||||||||||||
Lin Xia 67 year |
| ||||||||||||
Dong Lyu 49 year |
| ||||||||||||
Yuan Yuan Zhu 43 year |
| ||||||||||||
Rong Bing Yang 58 year |
| ||||||||||||
Hui Xian Yuan 65 year |
|
Latest Appointments: Luye Pharma Group Ltd.
Former Officers and Directors: Luye Pharma Group Ltd.
Insider | Positions held SinceUntil | ||||||
---|---|---|---|---|---|---|---|
Xin Sun |
| ||||||
You Xin Li |
| ||||||
Siu Kuen Lai |
| ||||||
Jiang Hua |
| ||||||
Shenghan Wang |
| ||||||
Dong Liu |
| ||||||
Jian Pan |
| ||||||
Xin Wang |
| ||||||
Yi Lan |
| ||||||
Xiang Jie Liu |
| ||||||
Dou Changlin |
| ||||||
Xi Ming Li |
| ||||||
Chin Fan Chong |
| ||||||
Chong Huat Tan |
| ||||||
Teck Chien Kong |
| ||||||
Wen De Chen |
| ||||||
Xin Yu Wang |
| ||||||
Chee Yong Tan |
| ||||||
Yu Bo Liu |
| ||||||
Kuo Chuan Kung |
| ||||||
Hai Hong |
| ||||||
Li Li |
| ||||||
Yuan Chong Liu |
| ||||||
Bao Ming Ge |
| ||||||
Li Ping Loh |
| ||||||
Shi Xu Li |
| ||||||
Hai Peng Diao |
| ||||||
Poh Noi Yeo |
|
Age distribution of managers
Parity Men Women
Male | 10 |
---|---|
Female | 3 |
Of which Executive Committee
Male | 2 |
---|---|
Female | 1 |
Of which Directors
Male | 10 |
---|---|
Female | 1 |
Environment
Governance
Controversy
MarketScreener is also available in this country: United States.
Switch edition